Evidence map›Paper›PMID 34524562›Full record

ReviewAnnals of intensive care2021

Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements.

G Montrucchio, T Lupia, D Lombardo, G Stroffolini, S Corcione, F G De Rosa, L Brazzi

Open access · goldAbstract readReview
In one paragraph

Review in Annals of intensive care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Characteristics of CD4Journal of intensive medicine · 2026
    Article
  7. Review
  8. Detection ofFrontiers in cellular and infection microbiology · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Monitoring the Occurrence ofMicroorganisms · 2025
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Invasive Fungal Infections Associated with COVID-19.Journal of fungi (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

G MontrucchioDepartment of Surgical Sciences, University of Turin, 10126, Turin, Italy. g.montrucchio@gmail.com.ORCID http://orcid.org/0000-0001-9341-965X
T LupiaUnit of Infectious Diseases, Cardinal Massaia Hospital, Asti, Italy.
D LombardoDepartment of Surgical Sciences, University of Turin, 10126, Turin, Italy.
G StroffoliniDepartment of Medical Sciences, University of Turin, Infectious Diseases, Città Della Salute E Della Scienza Hospital, Turin, Italy.
S CorcioneDepartment of Medical Sciences, University of Turin, Infectious Diseases, Città Della Salute E Della Scienza Hospital, Turin, Italy.
F G De RosaUnit of Infectious Diseases, Cardinal Massaia Hospital, Asti, Italy.
L BrazziDepartment of Surgical Sciences, University of Turin, 10126, Turin, Italy.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Sanitaria Locale di Asti · ITUniversity of Turin · ITTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive pulmonary aspergillosis (IPA) has always been a challenging diagnosis and risk factors an important guide to investigate specific population, especially in Intensive Care Unit. Traditionally recognized risk factors for IPA have been haematological diseases or condition associated with severe immunosuppression, lately completed by chronic conditions (such as obstructive pulmonary disease, liver cirrhosis, chronic kidney disease and diabetes), influenza infection and Intensive Care Unit (ICU) admission. Recently, a new association with SARS-CoV2 infection, named COVID-19-associated pulmonary aspergillosis (CAPA), has been reported worldwide, even if its basic epidemiological characteristics have not been completely established yet. In this narrative review, we aimed to explore the potential risk factors for the development of CAPA and to evaluate whether previous host factors or therapeutic approaches used in the treatment of COVID-19 critically ill patients (such as mechanical ventilation, intensive care management, corticosteroids, broad-spectrum antibiotics, immunomodulatory agents) may impact this new diagnostic category. Reviewing all English-language articles published from December 2019 to December 2020, we identified 21 papers describing risk factors, concerning host comorbidities, ICU management, and COVID-19 therapies. Although limited by the quality of the available literature, data seem to confirm the role of previous host risk factors, especially respiratory diseases. However, the attention is shifting from patients' related risk factors to factors characterizing the hospital and intensive care course, deeply influenced by specific features of COVID treatment itself. Prolonged invasive or non-invasive respiratory support, as well as the impact of corticosteroids and/or immunobiological therapies seem to play a pivotal role. ICU setting related factors, such as environmental factors, isolation conditions, ventilation systems, building renovation works, and temporal spread with respect to pandemic waves, need to be considered. Large, prospective studies based on new risk factors specific for CAPA are warranted to guide surveillance and decision of when and how to treat this particular population.

Indexed as

Acute respiratory distress syndromeCAPACOVID-19COVID-19-associated pulmonary aspergillosisInvasive pulmonary aspergillosisSARS-CoV-2

Identifiers

PMID34524562
PMCPMC8441237
OpenAlexW3200896545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.